Biologics Contract Development Market Size & Share, By Source (Mammalian, Microbial), Service Type, Indication (Oncology, Immunological Disorders) - Growth Trends, Regional Insights (U.S., Japan, South Korea, UK, Germany), Competitive Positioning, Global Forecast Report 2025-2034

التوقعات السوقية:

Biologics Contract Development Market size is set to increase from USD 8.5 billion in 2024 to USD 18.35 billion by 2034, with a projected CAGR exceeding 8% from 2025 to 2034. The industry revenue for 2025 is anticipated to hit USD 9.11 billion.

• Base Year Value (2024): USD 8.5 billion
• CAGR (2025-2034): 8%
• Forecast Year Value (2034): USD 18.35 billion
• Historical Data Period: 2019-2024
• Largest Region: North America
• Forecast Period: 2025-2034

سوق الديناميكية:

Growth Drivers & Opportunity:

Biologics contract development market is expected to witness significant growth due to increasing demand for personalized medicine, advancements in biotechnology, and rising investments in research and development.

Report Scope

Report Coverage	Details
Segments Covered	Source, Service, Indication
Regions Covered	• North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA)
Company Profiled	WuXi Biologics, Abzena, Fujifilm Diosynth Biotechnologies, KBI Biopharma, AGC Biologics, Thermo Fisher Scientific, Curia Global,, Genscript, Bionova Scientific,, BioXcellence, STC Biologics

Industry Restraints:

However, the market may face challenges such as stringent regulatory requirements and high costs associated with biologics development and manufacturing.

Growth Drivers & Opportunity:

Furthermore, the growing prevalence of chronic diseases and increasing adoption of biologics for the treatment of various diseases are expected to drive the growth of the market in the coming years.

Report Scope

Report Coverage	Details
Segments Covered	Source, Service, Indication
Regions Covered	• North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA)
Company Profiled	WuXi Biologics, Abzena, Fujifilm Diosynth Biotechnologies, KBI Biopharma, AGC Biologics, Thermo Fisher Scientific, Curia Global,, Genscript, Bionova Scientific,, BioXcellence, STC Biologics

Industry Restraints:

The complex manufacturing processes and the need for specialized expertise may act as restraints for the biologics contract development market.

التوقعات الإقليمية:

North America:

The Biologics Contract Development market in North America is dominated by the United States, which is one of the largest markets globally. The presence of key players, significant investments in research and development, and favorable government regulations contribute to the growth of the market in the region. Canada also plays a significant role in the North American market, with a growing number of contract development organizations offering biologics services.

Asia Pacific:

In Asia Pacific, China is a key player in the Biologics Contract Development market, with a rapidly expanding biopharmaceutical industry and increasing outsourcing activities. Japan and South Korea also contribute significantly to the market, with advanced infrastructure and technological capabilities supporting the growth of biologics contract development services in the region.

Europe:

Europe is a prominent market for Biologics Contract Development, with countries like the United Kingdom, Germany, and France leading the way. The presence of established contract development organizations, strong regulatory framework, and increasing demand for biologics services drive the growth of the market in Europe. The United Kingdom, in particular, is known for its expertise in biologics development, making it a key player in the European market.

تحليل التجزئة:

In terms of segmentation, the global Biologics Contract Development market is analyzed on the basis of Source, Service, Indication.

Mammalian Source:

The biologics contract development market for mammalian source is anticipated to witness significant growth due to the increasing demand for mammalian cell line-based biologics production. Mammalian cells offer several advantages such as high productivity, proper post-translational modifications, and ability to produce complex proteins. These factors are driving the market growth for mammalian source biologics contract development services.

Microbial Source:

The microbial source segment in the biologics contract development market is also expected to show substantial growth. Microbial expression systems, such as bacteria and yeast, are widely used for the production of recombinant proteins. These systems are cost-effective and can produce high yields of proteins in a short period of time. The microbial source segment is likely to experience growth due to the rising demand for microbial-based biologics development services.

Service Type:

The service type segment in the biologics contract development market includes cell line development, process development, analytical services, and others. Cell line development services are crucial for the production of biologics as they involve the selection and generation of stable cell lines for protein expression. Process development services focus on optimizing the bioprocess to enhance productivity and efficiency. Analytical services play a key role in ensuring the quality, safety, and efficacy of biologics. The demand for these services is expected to drive growth in the biologics contract development market.

Indication Oncology:

The oncology indication segment in the biologics contract development market is witnessing significant growth due to the increasing prevalence of cancer worldwide. Biologics play a crucial role in the treatment of various types of cancer by targeting specific molecules involved in cancer growth and progression. The development of biologics for oncology indications requires specialized expertise and services, driving the demand for biologics contract development in this segment.

Indication Immunological Disorders:

The immunological disorders indication segment in the biologics contract development market is also expected to show growth. Biologics are widely used in the treatment of various immunological disorders such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. The development of biologics for immunological disorders involves complex processes and specialized services, creating opportunities for growth in this segment of the biologics contract development market.

مشهد تنافسي:

Top Market Players:

Lonza Group

Boehringer Ingelheim GmbH

Samsung Biologics

WuXi Biologics

Catalent, Inc.

Thermo Fisher Scientific Inc.

Charles River Laboratories International, Inc.

Patheon N.V.

Toxikon Corporation

Evotec AG

The competitive landscape in the Biologics Contract Development Market is fierce and rapidly evolving with numerous companies vying for market share. These companies offer a range of services including cell line development, process development, analytical testing, and manufacturing of biologics for pharmaceutical and biotechnology companies globally. The market is characterized by intense competition, technological advancements, strategic collaborations, and acquisitions to strengthen their market position and expand their service offerings to meet the growing demand for biologics contract development services.

Table of Contents (ToC)

الفصل 1- المنهجية

• تعريف السوق
• الافتراضات الدراسية
• النطاق السوقي
  • الفصل
  • المناطق المشمولة
  • تقديرات القاعدة
  • حسابات التنبؤ
• مصادر البيانات
  • الابتدائي
  • المرحلة الثانوية

الفصل 2 - موجز تنفيذي

Chapter 3. Biologics Contract Development Market البصيرة

• عرض عام للأسواق
• فرص سائقي السوق
• تحديات تقييد الأسواق
• رأس المال التنظيمي
• تحليل النظم الإيكولوجية
• Technology " Innovation التوقعات
• التطورات الصناعية الرئيسية
  • الشراكة
  • الاندماج/الاقتناء
  • الاستثمار
  • إطلاق المنتجات
• تحليل سلسلة الإمدادات
• تحليل قوات بورتر الخمس
  • تهديد المنضمين الجدد
  • تهديد الغواصات
  • الصناعة
  • قوة الموصلات
  • قوة المحامين
• COVID-19 Impact
• PESTLE Analysis
  • رأس المال السياسي
  • رأس المال
  • رأس المال الاجتماعي
  • Technology Landscape
  • الشؤون القانونية
  • Environmental Landscape
• القدرة التنافسية
  • مقدمة
  • Company Market Share
  • مصفوفة لتحديد المواقع

Chapter 4. Biologics Contract Development Market الإحصاءات حسب الشرائح

• الاتجاهات الرئيسية
• تقديرات السوق والتنبؤات
  • الجدول
  • Chart

* قائمة أجزاء حسب نطاق/احتياجات التقرير

Chapter 5. Biologics Contract Development Market الإحصاءات حسب المنطقة

• الاتجاهات الرئيسية
  • مقدمة
  • الأثر الناجم عن الانفصال
• تقديرات السوق والتنبؤات
  • الجدول
  • Chart
• النطاق الإقليمي
  • أمريكا الشمالية
    • الولايات المتحدة
    • كندا
    • المكسيك
  • أوروبا
    • ألمانيا
    • المملكة المتحدة
    • فرنسا
    • إيطاليا
    • إسبانيا
    • بقية أوروبا
  • آسيا والمحيط الهادئ
    • الصين
    • اليابان
    • جنوب كوريا
    • سنغافورة
    • الهند
    • أستراليا
    • بقية أعضاء اللجنة
  • أمريكا اللاتينية
    • الأرجنتين
    • البرازيل
    • بقية أمريكا الجنوبية
  • الشرق الأوسط
    • GCC
    • جنوب أفريقيا
    • بقية الاتفاقات البيئية

* لا يُستفز *

الفصل 6. Company Data

• استعراض عام للأعمال التجارية
• المالية
• عرض المنتجات
• رسم الخرائط الاستراتيجية
  • الشراكة
  • الاندماج/الاقتناء
  • الاستثمار
  • إطلاق المنتجات
• التنمية الأخيرة
• الإقليمية
• SWOT Analysis

* قائمة شاملة وفقا لنطاق/احتياجات التقرير